Tenofovir-Based Antiretroviral Therapy in HBV–HIV Coinfection: Results from the TREAT Asia HIV Observational Database

Abstract

Background

The World Health Organization recommends HBV–HIV-coinfected individuals start antiretroviral therapy containing tenofovir. Here we describe first-line tenofovir use and treatment outcomes in coinfected patients in Asia.

Methods

HBV surface antigen positive patients enrolled in the TREAT Asia HIV Observational Database who started first-line antiretroviral therapy were included. Logistic regression adjusted for period of treatment initiation was used to determine factors associated with tenofovir use. Generalized estimating equations were used to evaluate factors associated with alanine transaminase levels and CD4⁺ T-cell count on treatment.

Results

There were 548 eligible patients, of whom 149 (27.2%) started tenofovir. Patients treated in high/high-middle income countries (odds ratio 4.4 versus low/low-middle, 95% CI 2.6, 7.4; P<0.001) and those with elevated baseline alanine transaminase (odds ratio 4.2 versus normal, 95% CI 2.4, 7.2; P<0.001) were more likely to receive tenofovir. Hepatitis C antibody positive patients (odds ratio 0.4 versus negative, 95% CI 0.2, 0.8; P=0.008) were less likely. In those starting antiretroviral therapy with elevated alanine transaminase, mean reduction after tenofovir initiation was 11.2 IU/l (95% CI 0.9, 21.6; P=0.034) lower compared with those using a non-tenofovir-based regimen although this did not significantly increase the chance of alanine transaminase normalization. Tenofovir use was not associated with a superior CD4⁺ T-cell response.

Conclusions

HBV–HIV-coinfected patients in Asia are most likely to receive tenofovir if they are treated in a high/high-middle income country, have elevated alanine transaminase levels and are hepatitis C antibody negative. Compared to other antiretroviral therapies, tenofovir-based regimens more effectively reduce liver inflammation in HBV–HIV-coinfection but do not result in superior CD4⁺ T-cell recovery.

References

Hoffmann

C.J.

, Thio

C.L.

Clinical implications of HIV and hepatitis B co-infection in Asia and Africa.

Lancet Infect Dis 2007; 7: 402–409.

UNAIDS. Global report - UNAIDS report on the global AIDS epidemic 2013. (Updated 1 November 2013. Accessed 13 April 2015.) Available from http://www.unaids.org/sites/default/files/media_asset/UNAIDS_Global_Report_2013_en_1.pdf.

WHO ART Guidelines Committee. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach – June 2013. (Updated 1 November 2013. Accessed 3 January 2014.) Available from http://apps.who.int/iris/bitstream/10665/85321/1/9789241505727_eng.pdf?ua=1.

Benhamou

, Bochet

, Thibault

Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients.

Hepatology 1999; 30: 1302–1306.

Matthews

G.V.

, Avihingsanon

, Lewin

S.R.

A randomized trial of combination hepatitis B therapy in HIV/ HBV coinfected antiretroviral naive individuals in Thailand.

Hepatology 2008; 48: 1062–1069.

Zhou

, Kumarasamy

, Ditangco

The TREAT Asia HIV Observational Database: baseline and retrospective data.

J Acquir Immune Defic Syndr 2005; 38: 174–179.

WHO. HIV testing, treatment and prevention. Generic tools for operational research (Updated 3 June 2009. Accessed 2 June 2015.) Available from http://www.who.int/hiv/pub/operational/generic/en/.

Cockcroft

D.W.

, Gault

M.H.

Prediction of creatinine clearance from serum creatinine.

Nephron 1976; 16: 31–41.

The World Bank. Countries and economies. (Updated 1 January 2015. Accessed 2 February 2015.) Available from http://data.worldbank.org/country.

10.

WHO. Guidelines for treatment of tuberculosis, fourth edition. (Updated 1 January 2010. Accessed 7 February 2014.) Available from http://www.who.int/tb/publications/2010/9789241547833/en/index.html.

11.

van Griensven

, Phirum

, Choun

, Thai

, De Weggheleire

, Lynen

Hepatitis B and C co-infection among HIV-infected adults while on antiretroviral treatment: long-term survival, CD4 cell count recovery and antiretroviral toxicity in Cambodia.

PLoS ONE 2014; 9: e88552.

12.

Sato

, Fujiyama

, Tanaka

Coinfection of hepatitis C virus in patients with chronic hepatitis B infection.

J Hepatol 1994; 21: 159–166.

13.

Sheen

I.S.

, Liaw

Y.F.

, Chu

C.M.

, Pao

C.C.

Role of hepatitis C virus infection in spontaneous hepatitis B surface antigen clearance during chronic hepatitis B virus infection.

J Infect Dis 1992; 165: 831–834.

14.

Kosi

, Reiberger

, Payer

B.A.

Five-year on-treatment efficacy of lamivudine-, tenofovir- and tenofovir + emtricitabine-based HAART in HBV-HIV-coinfected patients.

J Viral Hepat 2012; 19: 801–810.

15.

Chien

R.N.

, Liaw

Y.F.

, Atkins

Pretherapy alanine transaminase level as a determinant for hepatitis B e antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B. Asian Hepatitis Lamivudine Trial Group.

Hepatology 1999; 30: 770–774.

16.

Ridruejo

, Adrover

, Cocozzella

Effectiveness of entecavir in chronic hepatitis B NUC-naive patients in routine clinical practice.

Int J Clin Pract 2011; 65: 866–870.

17.

Wang

C.C.

, Tseng

K.C.

, Peng

C.Y.

Viral load and alanine aminotransferase correlate with serologic response in chronic hepatitis B patients treated with entecavir.

J Gastroenterol Hepatol 2013; 28: 46–50.

18.

Chu

C.J.

, Lee

S.D.

Hepatitis B virus/hepatitis C virus coinfection: epidemiology, clinical features, viral interactions and treatment.

J Gastroenterol Hepatol 2008; 23: 512–520.

19.

European Association For The Study Of The Liver.

EASL clinical practice guidelines: Management of chronic hepatitis B virus infection.

J Hepatol 2012; 57: 167–185.

20.

Durier

, Ruxrungtham

, Avihingsanon

Hepatitis C virus RNA and genotype, IL28B genotype, and liver fibrosis scores in a regional cohort of HIV-infected HCV-exposed patients under routine HIV care in Asia. AIDS Conference. 20–25 July 2014, Melbourne, Australia. Abstract LBPE14.

21.

De Luca

, Bugarini

, Lepri

A.C.

Coinfection with hepatitis viruses and outcome of initial antiretroviral regimens in previously naive HIV-infected subjects.

Arch Intern Med 2002; 162: 2125–2132.

22.

Law

W.P.

, Duncombe

C.J.

, Mahanontharit

Impact of viral hepatitis co-infection on response to antiretroviral therapy and HIV disease progression in the HIV-NAT cohort.

AIDS 2004; 18: 1169–1177.

23.

Idoko

, Meloni

, Muazu

Impact of hepatitis B virus infection on human immunodeficiency virus response to antiretroviral therapy in Nigeria.

Clin Infect Dis 2009; 49: 1268–1273.

24.

Omland

L.H.

, Weis

, Skinhoj

Impact of hepatitis B virus co-infection on response to highly active antiretroviral treatment and outcome in HIV-infected individuals: a nationwide cohort study.

HIV Med 2008; 9: 300–306.

25.

Wandeler

, Gsponer

, Mulenga

Zidovudine impairs immunological recovery on first-line antiretroviral therapy: collaborative analysis of cohort studies in southern Africa.

AIDS 2013; 27: 2225–2232.

26.

Puoti

, Cozzi-Lepri

, Paraninfo

Impact of lamivudine on the risk of liver-related death in 2,041 HBsAg- and HIV-positive individuals: results from an inter-cohort analysis.

Antivir Ther 2006; 11: 567–574.

27.

Park

S.Y.

, Kang

K.H.

, Park

J.H.

Clinical efficacy of AST/ ALT ratio and platelet counts as predictors of degree of fibrosis in HBV infected patients without clinically evident liver cirrhosis.

Korean J Gastroenterol 2004; 43: 246–251.

28.

Williams

A.L.

, Hoofnagle

J.H.

Ratio of serum aspartate to alanine aminotransferase in chronic hepatitis. Relationship to cirrhosis.

Gastroenterology 1988; 95: 734–739.